NCT00561964 - Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

July 31, 2005

Conditions

Hypertension

Interventions

DRUG

Irbesartan

Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)

DRUG

placebo

Placebo group: 2 placebo capsules daily as a single morning intake